The cyber security firm S2W Inc. has announced that it has raised more than $10 million of Series B funding. KDB Development Bank, YG Investment, Magellan Technology Investing, Ltte Ventures and DS Asset Management participated in this round led by LB Investment.
S2W is a cybersecurity data analysis firm and has a competitive global position to detect and react to new cyber threats like Dark Web and Ransomware. S2W has secured clients through its technology and data collaborations in the field of funding, telecoms, manufacturing and electricity trade.
In March 2020, S2W attracted a total of 3.5 million dollars for Series A and was assessed by its successful closing of Series B in just one and a half years for its high growth.
“S2W has the technology to work on the global stage and I expect them to play a huge role in the Metaverse society,” said Deok-soo Jang, chairman of DS Asset Management.
Ki-ho Park, CEO of LB Investment said, “S2W is now showing the compressed growth process of Palantir’s in the U.S. and is expected to expand into various fields such as blockchain, e-commerce, games, and entertainment in the future. And we will continue to support S2W to be the global leader in the industry.”
“We will focus on rapid growth, and we will prove to the world that companies pursuing the value of justice are superior in competitiveness and sustainability,” said Sangduk Suh, CEO of S2W.
CYFIRMA, a threat discovery and cyber-intelligence platform organization backed by Goldman Sachs, Zodius Capital, and Z3Partners, announced that Zuellig Pharma, a renowned healthcare services provider in Asia, has chosen DeCYFIR, a cloud-based, AI-powered cybersecurity platform, to gain greater insight into its external threat landscape and prevent cyberattacks.
Zuellig Pharma has boosted its cyber defence power with CYFIRMA’s DeCYFIR technology, allowing it to accurately detect cyberattacks at the early planning stage and take remedial actions to shut vulnerabilities before hackers can breach the network. The platform expands visibility into the exterior threat landscape by monitoring the dark web, hacker forums, and other closed communities for threat indicators that indicate hackers planning to use security flaws that could disrupt business.
“As a healthcare services company delivering life-saving medicines to those who need them the most, we own and operate some of the most advanced cold chain facilities, managing temperature-sensitive medicines through innovative and digitalized processes. The rapidly evolving threat landscape in the healthcare industry has shown us the importance of managing cybersecurity in dynamic ways, particularly as we continue rolling out more digitalization initiatives. CYFIRMA’s DeCYFIR will guide us in our response to cyber risks by providing us with real-time insights and early warnings to malicious activities targeting us,” said Mike Brewster, Vice President Technology, Zuellig Pharma.
“We are honoured to be working with Zuellig Pharma to deploy our DeCYFIR platform, which will play a pivotal role in helping them fend off cybercriminals who are out to pilfer intellectual property, conduct corporate espionage, cause business disruption and damage brand and reputation. Cybercrime has escalated rapidly in recent times, and this is a clear sign that businesses need to relook at how they are currently managing their cybersecurity strategies and programs. DeCYFIR’s ability to predict imminent attacks will give defenders the much-needed edge over cybercriminals,” said Kumar Ritesh, Founder and CEO, CYFIRMA. “